Bioinformatics analysis of diabetic retinopathy using functional protein sequences

Medical Hypotheses

Volumn 70, Issue 1, 2008, Pages 148-155

  Rao, Allam Appa ^a   Thota, Hanuman ^b   Gumpeny, Ramachandra Sridhar ^c   Akula, Annapurna ^a   Changalasetty, Suresh Babu ^b   Challa, Siva Reddy ^a   Ravavarapu, Tejaswi ^a   Akula, Siva Prasad ^b   Divakar, Ch ^d   Srinivas, K ^b   Das, Undurti N ^e  

^a ANDHRA UNIVERSITY   (India)

^b ACHARYA NAGARJUNA UNIVERSITY   (India)

^c Endocrine and Diabetes Centre   (India)

^d GITAM UNIVERSITY   (India)

^e UND LIFE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; CELL ADHESION MOLECULE; CYTOKINE; NITRIC OXIDE SYNTHASE; PROTEIN; VASCULOTROPIN;

ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; BIOINFORMATICS; BLINDNESS; CLUSTALW TECHNIQUE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG TARGETING; HUMAN; NEIGHBOR JOINING ALGORITHM; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHYLOGENETIC TREE; PHYLOGRAM; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK FACTOR; TECHNIQUE; TREATMENT PLANNING;

ALDEHYDE REDUCTASE; COMPUTATIONAL BIOLOGY; DIABETIC RETINOPATHY; HUMANS; NITRIC OXIDE SYNTHASE;

EID: 36349017655     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.03.033     Document Type: Article

References (69)

1. Way K.J., Katai N., and King G.L. Protein kinase C and the development of diabetic vascular complications. Diabet Med 18 (2001) 945-959
2. Wilkinson-Berka J.L. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 10 (2004) 3331-3348
3. Gurler B., Vural H., Yilmaz N., Oguz H., Satici A., and Aksoy N. The role of oxidative stress in diabetic retinopathy. Eye 14 Pt 5 (2000) 730-735
4. Yokoi M., Yamagishi S., Takeuchi M., Matsui T., Yoshida Y., Ohgami K., et al. Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. Brit J Ophthalmol 91 (2007) 397-398
5. Awata T., Neda T., Iizuka H., Kurihara S., Ohkubo T., Takata N., et al. Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes. Diabetes Care 27 (2004) 2184-2190
6. Starita C., Patel M., Katz B., and Adamis A.P. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthamol 39 (2007) 122-148
7. Miyamoto N., de Kozak Y., Jeanny J.C., Glotin A., Mascarelli F., Massin P., et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 50 (2007) 461-470
8. Chung S.S., and Chung S.K. Aldose reductase in diabetic microvascular complications. Curr Drug Targets 6 (2005) 475-486
9. Obrosova I.G., and Julius U.A. Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy. Curr Vasc Pharmacol 3 (2005) 267-283
10. Dagher Z., Park Y.S., Asnaghi V., Hoehn T., Gerhardinger C., and Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 53 (2004) 2404-2411
11. Cusick M., Chew E.Y., Ferris III F., Cox T.A., Chan C.C., and Kador P.F. Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Arch Ophthalmol 121 (2003) 1745-1751
12. Petrovic M.G., Peterlin B., Hawlina M., and Petrovic D. Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians. J Diabetes Complicat 19 (2005) 70-73
13. Leal E.C., Santiago A.R., and Ambrosio A.F. Old and new drug targets in diabetic retinopathy: from biochemical changes to inflammation and neurodegeneration. Curr Drug Targets CNS Neurol Disord 4 (2005) 421-434
14. Cheung A.K., Fung M.K., Lo A.C., Lam T.T., So K.F., Chung S.S., et al. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 54 (2005) 3119-3125
15. Sun W., Oates P.J., Coutcher J.B., Gerhardinger C., and Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 55 (2006) 2757-2762
16. Oishi N., Kubo E., Takamura Y., Maekawa K., Tanimoto T., and Akagi Y. Correlation between erythrocyte aldose reductase level and human diabetic retinopathy. Brit J Ophthalmol 86 (2002) 1363-1366
17. Kumaramanickavel G., Sripriya S., Ramprasad V.L., Upadyay N.K., Paul P.G., and Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmol Genet 24 (2003) 41-48
18. Wang Y., Ng M.C., Lee S.C., So W.Y., Tong P.C., Cockram C.S., et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 26 (2003) 2410-2415
19. Santos K.G., Tschiedel B., Schneider J., Souto K., and Roisenberg I. Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. Diabetes Res Clin Pract 61 (2003) 133-136
20. Srivastava S.K., Ramana K.V., and Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 26 (2005) 380-392
21. Tesfamariam B., Palacino J.J., Weisbrod R.M., and Cohen R.A. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 21 (1993) 205-211
22. Okuda Y., Kawashima K., Suzuki S., Asakura Y., Asano M., Tsurumaru K., et al. Restoration of nitric oxide production by aldose reductase inhibitor in human endothelial cells cultured in high-glucose medium. Life Sci 60 (1997) PL53-PL56
23. Okayama N., Omi H., Okouchi M., Imaeda K., Kato T., Akao M., et al. Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules. J Diabetes Complicat 16 (2002) 321-326
24. El-Remessy A.B., Abou-Mohamed G., Caldwell R.W., and Caldwell R.B. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 44 (2003) 3135-3143
25. Srivastava S.K., Ramana K.V., Chandra D., Srivastava S., and Bhatnagar A. Regulation of aldose reductase and the polyol pathway activity by nitric oxide. Chem Biol Interact 143-144 (2003) 333-340
26. Chaturvedi N. Modulation of the renin-angiotensin system and retinopathy. Heart 84 (2000) i29-i31
27. Jin-Zhong Zhang J.N., Gao L., Widness M., Xi X., and Kern T.S. Captopril inhibits glucose accumulation in retinal cells in diabetes. Invest Ophthalmol Vis Sci 4 (2003) 4001-4005
28. Yilmaz M.I., Sonmez A., Acikel C., Celik T., Bingol N., Pinar M., et al. Adiponectin may play a part in the pathogenesis of diabetic retinopathy. Eur J Endocrinol 151 (2004) 135-140
29. Wautier J.L., and Guillausseau P.J. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27 (2001) 535-542
30. Xu X., Li Z., Luo D., Huang Y., Zhu J., Wang X., et al. Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 241 (2003) 56-62
31. Lu M., Kuroki M., Amano S., Tolentino M., Keough K., Kim I., et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101 (1998) 1219-1224
32. Hammes H.P., Lin J., Wagner P., Feng Y., Vom Hagen F., Krzizok T., et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53 (2004) 1104-1110
33. Garpenstrand H., Ekblom J., Bäcklund L.B., Oreland L., and Rosenqvist U. Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in type 2 diabetes mellitus complicated by retinopathy. Diabet Med 16 (1999) 514-521
34. Hernandez C., Carrasco E., Casamitjana R., Deulofeu R., Garcia-Arumi J., and Simo R. Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care 28 (2005) 1941-1947
35. Meleth A.D., Agron E., Chan C.C., Reed G.F., Arora K., Byrnes G., et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 46 (2005) 4295-4301
36. Tikellis C., Cooper M.E., Twigg S.M., Burns W.C., and Tolcos M. Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. Endocrinology 145 (2004) 860-866
37. Shih S.C., Ju M., Liu N., Mo J.R., Ney J.J., and Smith L.E. Transforming growth factor beta1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyte-induced vascular survival in vivo. Proc Natl Acad Sci USA 100 (2003) 15859-15864
38. Kita T., Hata Y., Kano K., Miura M., Nakao S., Noda Y., et al. Transforming growth factor-β2 and connective tissue growth factor in proliferative vitroretinal diseases. Diabetes 56 (2007) 231-238
39. Wunderlich K., Senn B.C., Todesco L., Flammer J., and Meyer P. Regulation of connective tissue growth factor gene expression in retinal vascular endothelial cells by angiogenic growth factors. Graefes Arch Clin Exp Ophthalmol 238 (2000) 910-915
40. Chibber R., Ben-Mahmud B.M.B., Mann G.E., Zhang J.J., and Kohner E.M. Protein kinase C β2-dependent phosphorylation of core 2 GlcNAc-T promotes leukocyte-endothelial cell adhesion. Diabetes 52 (2003) 1519-1527
41. Canton A., Burgos R., Hernandez C., Mateo C., Segura R.M., Mesa J., et al. Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy. Brit J Ophthalmol 84 (2000) 732-735
42. Nishimura M., Nakano K., Ushiyama M., Nanbu A., Ohtsuka K., Takahashi H., et al. Increased serum concentrations of human hepatocyte growth factor in proliferative diabetic retinopathy. J Clin Endocrinol Metab 83 (1998) 195-198
43. Poulaki V., Joussen A.M., Mitsiades N., Mitsiades C.S., Iliaki E.F., and Adamis A.P. Insulin- like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol 165 (2004) 457-469
44. DeBosch B.J., Deo B.K., and Kumagai A.K. Effects of insulin-like growth factor-1 on retinal endothelial cell glucose transport and proliferation. J Neurochem 77 (2001) 1157-1167
45. Matsubara Y., Murata M., Maruyama T., Handa M., Yamagata N., Watanabe G., et al. Association between diabetic retinopathy and genetic variations in alpha 2 beta1 integrin, a platelet receptor for collagen. Blood 95 (2000) 1560-1564
46. Ljubimov A.V., Huang Z.S., Huang G.H., Burgeson R.F., Gullberg D., Miner J.H., et al. Human corneal epithelial basement membrane and integrin alterations in diabetes and diabetic retinopathy. J Histochem Cytochem 46 (1998) 1033-1041
47. Zintzaras E., Chatzoulis D.Z., Karabatsas C.H., and Stefanidis I. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet 50 (2005) 267-275
48. Harada C., Harada T., Mitamura Y., Quah H.M., Ohtsuka K., Kotake S., et al. Diverse NF-κB expression in epiretinal membranes after human diabetic retinopathy and proliferative vitreoretinopathy. Mol Vis 10 (2004) 31-36
49. Romeo G., Liu W.H., Asnaghi V., Kern T.S., and Lorenzi M. Activation of nuclear factor-κB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51 (2002) 2241-2248
50. n repeat of NOS2A in diabetic retinopathy. FASEB J 13 (1999) 1825-1832
51. Morris B.J., Markus A., Glenn C.L., Adams D.J., Colagiuri S., and Wang L. Association of a functional inducible nitric oxide synthase promoter variant with complications in type 2 diabetes. J Mol Med 80 (2002) 96-104
52. El-Remessy A.B., Abou-Mohamed G., Caldwell R.W., and Caldwell R.B. High-glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 44 (2003) 3135-3143
53. Mitamura Y., Tashimo A., Nakamura Y., Tagawa H., Ohtsuka K., Mizue Y., et al. Vitreous levels of placental growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care 25 (2002) 2352
54. Donnelly R., Idris I., and Forrester J.V. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Brit J Ophthalmol 88 (2004) 145-151
55. Hudson B.I., Stickland M.H., Futers T.S., and Grant P.J. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50 (2000) 1505-1511
56. van Hagen P.M., Baarsma G.S., Mooy C.M., Ercoskan E.M., ter Averst E., Hofland L.J., et al. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 143 (2000) S43-S51
57. Noda K., Ishida S., Inoue M., Obtata K., Oguchi Y., Okada Y., et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 44 (2003) 2163-2170
58. Seo D., Li H., Guedez L., Wingfield P., Diaz T., Salloum R., et al. TIP-2 mediated inhibition of angiogenesis-an MMP-independent mechanism. Cell 114 (2003) 171-180
59. Mitamura Y., Takeuchi S., Ohtsuka K., Matsuda A., Hiraiwa N., and Kusakabe M. Tenascin-C levels in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care 25 (2002) 1899
60. Majka S., McGuire P.G., and Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci 43 (2002) 260-266
61. Taverna M.J., Sola A., Guyot-Argenton C., Pacher N., Bruzzo F., Slama G., et al. Taq I polymorphism of the vitamin D receptor and risk of severe diabetic retinopathy. Diabetologia 45 (2002) 436-442
62. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
63. Joussen A.M., Poulaki V., Qin W., Kirchhof B., Mitsiades N., Wiegand S.J., et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 160 (2002) 501-509
64. Mohan I.K., and Das U.N. Oxidant stress, anti-oxidants and nitric oxide in noninsulin dependent diabetes mellitus. Med Sci Res 25 (1997) 55-57
65. Das U.N., Mohan I.K., Kumar V.K., Kumar S.K., and Sekhar C.C. Beneficial effect of l-arginine in non-insulin dependent diabetes mellitus: a potential role for nitric oxide. Med Sci Res 21 (1993) 669-670
66. Ramana K.V., Chandra D., Srivastava S., Bhatnagar A., and Srivastava S.K. Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells. FASEB J 17 (2003) 417-425
67. Obrosova I.G., Minchenko A.G., Vasupuram R., White L., Abatan O.I., Kumagai A.K., et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52 (2003) 864-871
68. Boulanger E., Grossin N., Wautier M.P., Taamma R., and Wautier J.L. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 71 (2007) 126-133
69. Patel J.I., Hykin P.G., Gregor Z.J., Boulton M., and Cree I.A. Angiopoietin concentrations in diabetic retinopathy. Brit J Ophthalmol 89 (2005) 480-483